Pulmonary arterial hypertension in SLE: What do we know?

Lupus

Volumn 22, Issue 12, 2013, Pages 1274-1285

  Prabu, A ^a,b   Gordon, C ^a,c  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b WORCESTERSHIRE ACUTE HOSPITALS NHS TRUST   (United Kingdom)

^c SANDWELL AND WEST BIRMINGHAM HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

epidemiology; pregnancy; prognosis; Pulmonary hypertension; systemic lupus erythematosus; treatment

Indexed keywords

BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; PHOSPHODIESTERASE V INHIBITOR; PHOSPHOLIPID ANTIBODY; PROSTACYCLIN DERIVATIVE; SILDENAFIL; STEROID;

ANTICOAGULATION; ARTICLE; AWARENESS; CLINICAL TRIAL; DISEASE REGISTRY; DISEASE SEVERITY; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MORBIDITY; PATHOGENESIS; PREGNANCY; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; SCREENING; STEROID THERAPY; SURVIVAL; SYSTEMIC LUPUS ERYTHEMATOSUS; TRICUSPID VALVE REGURGITATION;

EPIDEMIOLOGY; PREGNANCY; PROGNOSIS; PULMONARY HYPERTENSION; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT;

ANTIBODIES, ANTIPHOSPHOLIPID; EARLY DIAGNOSIS; ECHOCARDIOGRAPHY; FEMALE; HUMANS; HYPERTENSION, PULMONARY; LUPUS ERYTHEMATOSUS, SYSTEMIC; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; SURVIVAL;

EID: 84885639091     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203313505010     Document Type: Article

References (100)

1. Goupille P, Fauchier L, Babuty D, Fauchier JP, Valat JP. Precapillary pulmonary hypertension dramatically improved with high doses of corticosteroids during systemic lupus erythematosus. J Rheumatol. 1994 ; 21: 1976-1977
2. Robbins IM, Gaine SP, Schilz R, Tapson VF, Rubin LJ, Loyd JE. Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus. Chest. 2000 ; 117: 14-18
3. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2009 ; 54: S43 - S54
4. Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland. Thorax 2008; 63(Suppl 2): ii1-ii41.
5. Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2009 ; 34: 1219-1263
6. Battle RW, Davitt MA, Cooper SM, et al. Prevalence of pulmonary hypertension in limited and diffuse scleroderma. Chest. 1996 ; 110: 1515-1519
7. Murata I, Kihara H, Shinohara S, Ito K. Echocardiographic evaluation of pulmonary arterial hypertension in patients with progressive systemic sclerosis and related syndromes. Jpn Circ J. 1992 ; 56: 983-991
8. Murata I, Takenaka K, Yoshinoya S, et al. Clinical evaluation of pulmonary hypertension in systemic sclerosis and related disorders. A Doppler echocardiographic study of 135 Japanese patients. Chest. 1997 ; 111: 36-43
9. Pope JE, Lee P, Baron M, et al. Prevalence of elevated pulmonary arterial pressures measured by echocardiography in a multicenter study of patients with systemic sclerosis. J Rheumatol. 2005 ; 32: 1273-1278
10. Wigley FM, Lima JA, Mayes M, McLain D, Chapin JL, Ward-Able C. The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary health care level of community-based rheumatologists (the UNCOVER study). Arthritis Rheum. 2005 ; 52: 2125-2132
11. Yamane K, Ihn H, Asano Y, et al. Clinical and laboratory features of scleroderma patients with pulmonary hypertension. Rheumatology (Oxford). 2000 ; 39: 1269-1271
12. Ungerer RG, Tashkin DP, Furst D, et al. Prevalence and clinical correlates of pulmonary arterial hypertension in progressive systemic sclerosis. Am J Med. 1983 ; 75: 65-74
13. Salerni R, Rodnan GP, Leon DF, Shaver JA. Pulmonary hypertension in the CREST syndrome variant of progressive systemic sclerosis (scleroderma). Ann Intern Med. 1977 ; 86: 394-399
14. Mukerjee D, St George D, Coleiro B, et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: Application of a registry approach. Ann Rheum Dis. 2003 ; 62: 1088-1093
15. Hachulla E, Gressin V, Guillevin L, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: A French nationwide prospective multicenter study. Arthritis Rheum. 2005 ; 52: 3792-3800
16. Avouac J, Airo P, Meune C, et al. Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and meta-analysis of 5 studies. J Rheumatol. 2010 ; 37: 2290-2298
17. Simonson JS, Schiller NB, Petri M, Hellmann DB. Pulmonary hypertension in systemic lupus erythematosus. J Rheumatol. 1989 ; 16: 918-925
18. Quismorio FP, Sharma O, Koss M, et al. Immunopathologic and clinical studies in pulmonary hypertension associated with systemic lupus erythematosus. Semin Arthritis Rheum. 1984 ; 13: 349-359
19. Prabu A, Patel K, Yee CS, et al. Prevalence and risk factors for pulmonary arterial hypertension in patients with lupus. Rheumatology (Oxford). 2009 ; 48: 1506-1511
20. Winslow TM, Ossipov MA, Fazio GP, Simonson JS, Redberg RF, Schiller NB. Five-year follow-up study of the prevalence and progression of pulmonary hypertension in systemic lupus erythematosus. Am Heart J. 1995 ; 129: 510-515
21. Fayemi AO. Pulmonary vascular disease in systemic lupus erythematosus. Am J Clin Pathol. 1976 ; 65: 284-290
22. Chung SM, Lee CK, Lee EY, Yoo B, Lee SD, Moon HB. Clinical aspects of pulmonary hypertension in patients with systemic lupus erythematosus and in patients with idiopathic pulmonary arterial hypertension. Clin Rheumatol. 2006 ; 25: 866-872
23. Fois E, Le Guern V, Dupuy A, Humbert M, Mouthon L, Guillevin L. Noninvasive assessment of systolic pulmonary artery pressure in systemic lupus erythematosus: Retrospective analysis of 93 patients. Clin Exp Rheumatol. 2010 ; 28: 836-841
24. Xia YK, Tu SH, Hu YH, et al. Pulmonary hypertension in systemic lupus erythematosus: A systematic review and analysis of 642 cases in Chinese population. Rheumatol Int. 2013 ; 33: 1211-1217
25. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: Results from a national registry. Am J Respir Crit Care Med. 2006 ; 173: 1023-1030
26. Peacock AJ, Murphy NF, McMurray JJ, Caballero L, Stewart S. An epidemiological study of pulmonary arterial hypertension. Eur Respir J. 2007 ; 30: 104-109
27. Condliffe R, Kiely DG, Peacock AJ, et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med. 2009 ; 179: 151-157
28. Chung L, Liu J, Parsons L, et al. Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: Identifying systemic sclerosis as a unique phenotype. Chest. 2010 ; 138: 1383-1394
29. Dorfmuller P, Perros F, Balabanian K, Humbert M. Inflammation in pulmonary arterial hypertension. Eur Respir J. 2003 ; 22: 358-363
30. Tuder RM, Groves B, Badesch DB, Voelkel NF. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol. 1994 ; 144: 275-285
31. Fisher MR, Forfia PR, Chamera E, et al. Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Respir Crit Care Med. 2009 ; 179: 615-621
32. Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009 ; 30: 2493-2537
33. Howard LS, Grapsa J, Dawson D, et al. Echocardiographic assessment of pulmonary hypertension: Standard operating procedure. Eur Respir Rev. 2012 ; 21: 239-248
34. Goh NS, Desai SR, Veeraraghavan S, et al. Interstitial lung disease in systemic sclerosis: A simple staging system. Am J Respir Crit Care Med. 2008 ; 177: 1248-1254
35. Hsu VM, Moreyra AE, Wilson AC, et al. Assessment of pulmonary arterial hypertension in patients with systemic sclerosis: Comparison of noninvasive tests with results of right-heart catheterization. J Rheumatol. 2008 ; 35: 458-465
36. Steen V, Medsger TA. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum. 2003 ; 48: 516-522
37. Mukerjee D, St George D, Knight C, et al. Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatology (Oxford). 2004 ; 43: 461-466
38. York M, Farber HW. Pulmonary hypertension: Screening and evaluation in scleroderma. Curr Opin Rheumatol. 2011 ; 23: 536-544
39. Dhala A. Pulmonary arterial hypertension in systemic lupus erythematosus: Current status and future direction. Clin Dev Immunol. 2012 ; 2012: 854941-854941
40. Badesch DB, Champion HC, Sanchez MA, et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009 ; 54: S55 - S66
41. Kovacs G, Berghold A, Scheidl S, Olschewski H. Pulmonary arterial pressure during rest and exercise in healthy subjects: A systematic review. Eur Respir J. 2009 ; 34: 888-894
42. Naeije R, Melot C, Niset G, Delcroix M, Wagner PD. Mechanisms of improved arterial oxygenation after peripheral chemoreceptor stimulation during hypoxic exercise. J Appl Physiol. 1993 ; 74: 1666-1671
43. Asherson RA, kworth-Young CG, Boey ML, et al. Pulmonary hypertension in systemic lupus erythematosus. Br Med J (Clin Res Ed). 1983 ; 287: 1024-1025
44. Asherson RA, Oakley CM. Pulmonary hypertension and systemic lupus erythematosus. J Rheumatol. 1986 ; 13: 1-5
45. Asherson RA. Pulmonary hypertension in systemic lupus erythematosus. J Rheumatol. 1990 ; 17: 414-415
46. Cefle A, Inanc M, Sayarlioglu M, et al. Pulmonary hypertension in systemic lupus erythematosus: Relationship with antiphospholipid antibodies and severe disease outcome. Rheumatol Int. 2011 ; 31: 183-189
47. Farzaneh-Far A, Roman MJ, Lockshin MD, et al. Relationship of antiphospholipid antibodies to cardiovascular manifestations of systemic lupus erythematosus. Arthritis Rheum. 2006 ; 54: 3918-3925
48. Asherson RA, Higenbottam TW, Dinh Xuan AT, Khamashta MA, Hughes GR. Pulmonary hypertension in a lupus clinic: Experience with twenty-four patients. J Rheumatol. 1990 ; 17: 1292-1298
49. Kasparian A, Floros A, Gialafos E, et al. Raynaud's phenomenon is correlated with elevated systolic pulmonary arterial pressure in patients with systemic lupus erythematosus. Lupus. 2007 ; 16: 505-508
50. Li EK, Tam LS. Pulmonary hypertension in systemic lupus erythematosus: Clinical association and survival in 18 patients. J Rheumatol. 1999 ; 26: 1923-1929
51. Shen JY, Chen SL, Wu YX, et al. Pulmonary hypertension in systemic lupus erythematosus. Rheumatol Int. 1999 ; 18: 147-151
52. Lian F, Chen D, Wang Y, et al. Clinical features and independent predictors of pulmonary arterial hypertension in systemic lupus erythematosus. Rheumatol Int. 2012 ; 32: 1727-1731
53. Li MT, Ai J, Tian Z, et al. Prevalence of anti-endothelial cell antibodies in patients with pulmonary arterial hypertension associated with connective tissue diseases. Chin Med Sci J. 2010 ; 25: 27-31
54. Arends SJ, Damoiseaux J, Duijvestijn A, et al. Prevalence of anti-endothelial cell antibodies in idiopathic pulmonary arterial hypertension. Eur Respir J. 2010 ; 35: 923-925
55. Johnson SR, Gladman DD, Urowitz MB, Ibanez D, Granton JT. Pulmonary hypertension in systemic lupus. Lupus. 2004 ; 13: 506-509
56. Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL. Primary pulmonary hypertension: Natural history and the importance of thrombosis. Circulation. 1984 ; 70: 580-587
57. Hoeper MM, Sosada M, Fabel H. Plasma coagulation profiles in patients with severe primary pulmonary hypertension. Eur Respir J. 1998 ; 12: 1446-1449
58. Huber K, Beckmann R, Frank H, Kneussl M, Mlczoch J, Binder BR. Fibrinogen, t-PA, and PAI-1 plasma levels in patients with pulmonary hypertension. Am J Respir Crit Care Med. 1994 ; 150: 929-933
59. Herve P, Humbert M, Sitbon O, et al. Pathobiology of pulmonary hypertension. The role of platelets and thrombosis. Clin Chest Med. 2001 ; 22: 451-458
60. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med. 1992 ; 327: 76-81
61. Galie N, Manes A, Farahani KV, et al. Pulmonary arterial hypertension associated to connective tissue diseases. Lupus. 2005 ; 14: 713-717
62. Badesch DB, Hill NS, Burgess G, et al. Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. J Rheumatol. 2007 ; 34: 2417-2422
63. Denton CP, Humbert M, Rubin L, Black CM. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: A subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis. 2006 ; 65: 1336-1340
64. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: A randomised placebo-controlled study. Lancet. 2001 ; 358: 1119-1123
65. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002 ; 346: 896-903
66. Denton CP, Pope JE, Peter HH, et al. Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases. Ann Rheum Dis. 2008 ; 67: 1222-1228
67. Tanaka E, Harigai M, Tanaka M, Kawaguchi Y, Hara M, Kamatani N. Pulmonary hypertension in systemic lupus erythematosus: Evaluation of clinical characteristics and response to immunosuppressive treatment. J Rheumatol. 2002 ; 29: 282-287
68. Groen H, Bootsma H, Postma DS, Kallenberg CG. Primary pulmonary hypertension in a patient with systemic lupus erythematosus: Partial improvement with cyclophosphamide. J Rheumatol. 1993 ; 20: 1055-1057
69. Gonzalez-Lopez L, Cardona-Munoz EG, Celis A, et al. Therapy with intermittent pulse cyclophosphamide for pulmonary hypertension associated with systemic lupus erythematosus. Lupus. 2004 ; 13: 105-112
70. Sanchez O, Sitbon O, Jais X, Simonneau G, Humbert M. Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. Chest. 2006 ; 130: 182-189
71. Jais X, Launay D, Yaici A, et al. Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: A retrospective analysis of twenty-three cases. Arthritis Rheum. 2008 ; 58: 521-531
72. Miyamichi-Yamamoto S, Fukumoto Y, Sugimura K, et al. Intensive immunosuppressive therapy improves pulmonary hemodynamics and long-term prognosis in patients with pulmonary arterial hypertension associated with connective tissue disease. Circ J. 2011 ; 75: 2668-2674
73. McLaughlin VV, Presberg KW, Doyle RL, et al. Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004 ; 126: 78S - 92S
74. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991 ; 115: 343-349
75. Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation. 2010 ; 122: 156-163
76. Chow SL, Chandran V, Fazelzad R, Johnson SR. Prognostic factors for survival in systemic lupus erythematosus associated pulmonary hypertension. Lupus. 2012 ; 21: 353-364
77. Koh ET, Lee P, Gladman DD, bu-Shakra M. Pulmonary hypertension in systemic sclerosis: An analysis of 17 patients. Br J Rheumatol. 1996 ; 35: 989-993
78. Asherson RA, Hackett D, Gharavi AE, Harris EN, Kennedy HG, Hughes GR. Pulmonary hypertension in systemic lupus erythematosus: A report of three cases. J Rheumatol. 1986 ; 13: 416-420
79. Minai O. An update in pulmonary hypertension in systemic lupus erythematosus-do we need to know about it?. Lupus. 2009 ; 18: 92-92
80. Martin WL, Gordon C, Kilby MD. Systemic lupus erythematosus. Lancet. 2001 ; 358: 586-586
81. Weiss BM, Zemp L, Seifert B, Hess OM. Outcome of pulmonary vascular disease in pregnancy: A systematic overview from 1978 through 1996. J Am Coll Cardiol. 1998 ; 31: 1650-1657
82. Weiss BM, Hess OM. Pulmonary vascular disease and pregnancy: Current controversies, management strategies, and perspectives. Eur Heart J. 2000 ; 21: 104-115
83. Royal College of Obstetricians and Gynaecologists. Why mothers die. Report on confidential enquiries into maternal deaths in the United Kingdom 1997-1999. London: RCOG, 2001.
84. Greenstone MA. Delayed diagnosis of systemic lupus erythematosus associated pulmonary hypertension. Br J Rheumatol. 1991 ; 30: 391-391
85. McMillan E, Martin WL, Waugh J, et al. Management of pregnancy in women with pulmonary hypertension secondary to SLE and anti-phospholipid syndrome. Lupus. 2002 ; 11: 392-398
86. Bedard E, Dimopoulos K, Gatzoulis MA. Has there been any progress made on pregnancy outcomes among women with pulmonary arterial hypertension?. Eur Heart J. 2009 ; 30: 256-265
87. Jais X, Olsson KM, Barbera JA, et al. Pregnancy outcomes in pulmonary arterial hypertension in the modern management era. Eur Respir J. 2012 ; 40: 881-885
88. McQuillan BM, Picard MH, Leavitt M, Weyman AE. Clinical correlates and reference intervals for pulmonary artery systolic pressure among echocardiographically normal subjects. Circulation. 2001 ; 104: 2797-2802
89. Foale R, Nihoyannopoulos P, McKenna W, et al. Echocardiographic measurement of the normal adult right ventricle. Br Heart J. 1986 ; 56: 33-44
90. Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: A report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005 ; 18: 1440-1463
91. Kitabatake A, Inoue M, Asao M, et al. Noninvasive evaluation of pulmonary hypertension by a pulsed Doppler technique. Circulation. 1983 ; 68: 302-309
92. Maeba H, Nakatani S, Sugawara M, et al. Different time course of changes in tricuspid regurgitant pressure gradient and pulmonary artery flow acceleration after pulmonary thromboendarterectomy: Implications for discordant recovery of pulmonary artery pressure and compliance. Circ J. 2007 ; 71: 1771-1775
93. Vahanian A, Baumgartner H, Bax J, et al. Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J. 2007 ; 28: 230-268
94. Yoshida K, Yoshikawa J, Shakudo M, et al. Color Doppler evaluation of valvular regurgitation in normal subjects. Circulation. 1988 ; 78: 840-847
95. Triulzi M, Gillam LD, Gentile F, Newell JB, Weyman AE. Normal adult cross-sectional echocardiographic values: Linear dimensions and chamber areas. Echocardiography. 1984 ; 1: 403-426
96. Wang J, Prakasa K, Bomma C, et al. Comparison of novel echocardiographic parameters of right ventricular function with ejection fraction by cardiac magnetic resonance. J Am Soc Echocardiogr. 2007 ; 20: 1058-1064
97. Anavekar NS, Skali H, Bourgoun M, et al. Usefulness of right ventricular fractional area change to predict death, heart failure, and stroke following myocardial infarction (from the VALIANT ECHO Study). Am J Cardiol. 2008 ; 101: 607-612
98. Forfia PR, Fisher MR, Mathai SC, et al. Tricuspid annular displacement predicts survival in pulmonary hypertension. Am J Respir Crit Care Med. 2006 ; 174: 1034-1041
99. Tei C, Dujardin KS, Hodge DO, et al. Doppler echocardiographic index for assessment of global right ventricular function. J Am Soc Echocardiogr. 1996 ; 9: 838-847
100. Santamore WP, Dell'Italia LJ. Ventricular interdependence: Significant left ventricular contributions to right ventricular systolic function. Prog Cardiovasc Dis. 1998 ; 40: 289-308